Consensus Collegium Pharmaceutical, Inc.

Stocks

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 00:00:00 01/07/2026 +04			5-day change	1st Jan Change
36.20 ^USD	+0.61%		+4.56%	-21.81%

05-16	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director	CI
05-12	Collegium completes acquisition of Azstarys® from Corium Therapeutics	RE

Evolution of the Average Target: Collegium Pharmaceutical, Inc.

Evolution of the Target Price: Collegium Pharmaceutical, Inc.

Changes in Analyst Recommendations: Collegium Pharmaceutical, Inc.

afa1b.pCwyqcAcpDEV8FNNgX3fYpbD8W2VPd16j9TDenof47s.nU5r6PR3w1BgpzsM7g25MeyVgwvSSpUbwpnuGzlUrPDWHECcj3DoblzHJA~e9462d64181fc846912c71509deb16e4

Analysts' recommendations: Collegium Pharmaceutical, Inc.

02-10	Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating	MT
01-07	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $55 From $48, Maintains Buy Rating	MT
12-09	Barclays Initiates Collegium Pharmaceutical at Overweight With $58 Price Target	MT
11-07	Truist Raises Price Target on Collegium Pharmaceutical to $48 From $45, Keeps Buy Rating	MT
08/08/25	Truist Raises Price Target on Collegium Pharmaceutical to $45 From $42, Keeps Buy Rating	MT
07/08/25	Collegium Pharma Q2 revenue beats analyst expectations	RE
10/01/25	Needham Upgrades Collegium Pharmaceutical to Buy From Hold, Price Target is $46	MT
09/08/24	Truist Securities Adjusts Price Target on Collegium Pharmaceutical to $42 From $40, Maintains Buy Rating	MT
30/07/24	HC Wainwright Upgrades Collegium Pharmaceutical to Buy From Neutral, Price Target is $47	MT
07/06/24	Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	MT
10/05/24	Needham Downgrades Collegium Pharmaceutical to Hold From Buy	MT
10/05/24	Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	MT
26/02/24	Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	MT
26/02/24	Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	MT
04/01/24	Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating	MT
04/01/24	Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30	MT
25/08/23	Needham Adjusts Price Target on Collegium Pharmaceutical to $36 From $35, Maintains Buy Rating	MT
02/05/23	Jefferies Assumes Collegium Pharmaceutical at Buy With $30 Price Target	MT
05/01/23	Needham Adjusts Price Target on Collegium Pharmaceutical to $35 From $34, Maintains Buy Rating	MT
04/11/22	Needham Adjusts Price Target on Collegium Pharmaceutical to $34 From $36, Maintains Buy Rating	MT
08/08/22	HC Wainwright Downgrades Collegium Pharmaceutical to Neutral From Buy	MT
06/04/22	Needham Adjusts Collegium Pharmaceutical's Price Target to $36 From $34, Keeps Buy Rating	MT
22/02/22	Piper Sandler Adjusts Collegium Pharmaceutical's Price Target to $42 From $36, Reiterates Overweight Rating	MT
15/02/22	Needham Adjusts Collegium Pharmaceutical's Price Target to $34 From $28, Reiterates Buy Rating	MT
15/02/22	HC Wainwright Adjusts Collegium Pharmaceutical's Price Target to $29 From $26, Reiterates Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	COLLEGIUM PHARMACEUTICAL, INC.					+50.09%
	ELI LILLY AND COMPANY					+1.75%
	JOHNSON & JOHNSON					+1.39%
	ABBVIE INC.					+1.79%
	ROCHE HOLDING AG					+7.86%
	ASTRAZENECA PLC					+16.72%
	NOVARTIS AG					-1.47%
	NOVO NORDISK A/S					+0.2%
	AMGEN INC.					-2.03%
	GILEAD SCIENCES, INC.					+24.8%
	Average					+10.11%
	Weighted average by Cap.					+3.93%